Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis

Cystic Fibrosis in Children Clinical Trial

Official title:

Combined Effect of CFTR Protein Modulator Drugs and Exercise on Pulmonary Function, Fitness, Sweat Test and Quality of Life in Children With Cystic Fibrosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04415268
• Other study ID #: CIPI/20/119
• Status: Withdrawn
• Phase: N/A
• Start date: June 9, 2020
• Est. completion date: May 15, 2021

Study information

• Verified date: December 2023
• Source: Universidad Europea de Madrid
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to assess the effects of programmed exercise combined with CFTR protein modulator drugs in the cardiorespiratory fitness, strength, functional capacity and agility in a group of young patients with Cystic Fibrosis.

Description:

The present study is a new clinical trial that extends our previous work intended to assess the effect of programmed exercise with or without electrical stimulation on cardiorespiratory fitness, strength, functional capacity and agility in a group of young patients with Cystic Fibrosis (ECOMIRIN) registered at ClinicalTrials.gov (Identifier: NCT04153669). After finishing the study, a subset of the participants was treated with either TEZ/IVA or LUM/IVA per standard of care, as they were considered candidates according to the AEMPS (https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES). Those patients are expected to complete five months of pharmacological treatment without exercise by June 2020. Primary Objective To evaluate the effect of an exercise program on physical fitness in cystic fibrosis patients after 5 months of administration of LUM/IVA or TEZ/IVA in comparison to the effect produced by the same exercise program before administration of the drug. Secondary Objectives Other specific objectives include comparing the beneficial effects of exercise and LUM/IVA or TEZ/IVA on: 1) cardiorespiratory function and muscle strength; 2) the concentration of chlorine in sweat; and 3) quality of life.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 15, 2021
• Est. primary completion date: January 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• In order to be included, patients must have participated in the ECOMIRIN clinical trial (ClinicalTrials.gov Identifier: NCT04153669).
• They must have a previous CF diagnosis, defined as: sweat chlorine = 60 mEq/L and/or carry two variants of the CFTR gene characterized as pathogenic.
• Age 6-18 years; eligible to receive treatment with TEZ/IVA or LUM/IVA according to the AEMPS (LUM/IVA for 6-11 year-old children homozygous for the F508del mutation; TEZ/IVA for = 12 year-old children homozygous for the Phe508del mutation, as well as heterozygous for the F508 mutation plus one of the following mutations: P67L, R117C, L206W, R352Q, A455E, D579G, 711 + 3A G, S945L, S977F, R1070W, D1152H, 2789 + 5G A, 3272-26A G, and 3849 + 10kbC T);
• Agreement to collaborate in performing static and dynamic pulmonary function tests.
• Consent of children and/or parents or legal guardians to participate in the study after having read and understood the informed consent form.

Exclusion Criteria:

• CF patients not consenting to participate in the study at any time after reading and understanding the informed consent form will be excluded.
• CF patients who are not eligible to receive treatment with TEZ/IVA or LUM/IVA according to the AEMPS during the course of the study will be excluded.
• Study participants will be excluded if they test positive for any contagious viral infection that may affect the outcomes (e.g. SARS-CoV-2).

Related Conditions & MeSH terms

• Cystic Fibrosis
• Cystic Fibrosis in Children
• Fibrosis

Intervention

Behavioral:
• Exercise
Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
• Unsupervised exercise
Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.

Drug:
• CFTR Modulators
Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor. For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night. https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES

Locations

Country	Name	City	State
Spain	Escuela de Doctorado e Investigacion, Universidad Europea	Villaviciosa De Odón

Sponsors (1)

Lead Sponsor	Collaborator
Universidad Europea de Madrid

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Strength	Changes in strength will be measured using a five repetition maximum test (5RM)	Four assessment points throughout the study: baseline and after each 8-week intervention
Primary	Change in Cardiorespiratory Fitness	Changes in cardiorespiratory fitness will be measured using a cardiopulmonary exercise test (CPET)	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Changes in Forced expiratory volume in 1 second (FEV1)	Changes in FEV1 will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Changes in Forced vital capacity (FVC)	Changes in FVC will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Changes in FEV1/FVC ratio (FEV1%)	Changes in FEV1/FVC ratio (FEV1%) will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Changes in Forced expiratory flow (FEF)	Changes in FEF will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Changes in Physical Activity Questionnaire (PAQ) for children and adolescents	Changes in physical activity levels will be measured using PAQ-C for children under 14 years of age and PAQ-A for adolescents over 14 years of age.; Items 1 to 9 will be used in the physical activity composite score, and means will be calculated to obtain the final PAQ-C activity summary score. Items 1 to 8 will be used in the physical activity composite score, and means will be calculated to obtain the final PAQ-A activity summary score.; A score of 1 indicates low physical activity, whereas a score of 5 indicates high physical activity.	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Change in quality of life: Cystic Fibrosis-Questionnaire-Revised (CFQ-R)	Changes in quality of life will be measures with the Cystic Fibrosis-Questionnaire-Revised (CFQ-R).; Scores for each health related quality of life domain are calculated; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.	Four assessment points throughout the study: baseline and after each 8-week intervention
Secondary	Sweat chloride level	Chloride concentration in sweat (mEq/L) will be measured in the laboratory using an MK II Chloride Analyzer 926S	Four assessment points throughout the study: baseline and after each 8-week intervention